In the SU2C/PCF Dream Team cohort, 10% of patients with metastatic PC have evidence of MBTPS2 amplification, along with alterations in SREBP1 (6%), and SREBP2 (2.8%), relatively higher when compared to patients without metastasis (the TCGA Firehose Legacy cohort [20]) (Fig. 2e). This evidence concerns the gene MBTPS2 and pachyonychia congenita.